Prelude Therapeutics Incorporated PRLD
$5.67
+2.16%
at last close
Market Cap$442.91 million
P/E Ratio—
Div Yield—
Volume20.7K
52-Week Range
$0.75$5.91
Analyst Ratings
- Consensus
- Buy — 4 Buy · 0 Hold · 0 Sell (4 analysts)
- Avg. Price Target
- $6.50 (+14.6% upside)
Key Stats
- Today's Range
- $5.45 – $5.68
- 50-Day Range
- $3.74 – $5.91
- 52-Week Range
- $0.75 – $5.91
- Volume
- 21K shs
- Average Volume
- 371K shs
- Market Cap
- $442.91 million
- P/E Ratio
- —
- Dividend Yield
- —
Valuation
- P/E Ratio
- —
- Price / Book
- 3.31
- Price / Sales
- 19.75
Short Interest
- Short Interest
- 0.01%
- Days to Cover
- 1.00
Financials (TTM)
- Revenue
- $22.42 million
- Net Income
- $-60,488,000
- Net Margin
- -269.75%
- Return on Equity
- -45.23%
- Debt-to-Equity
- —
About Prelude Therapeutics Incorporated
Prelude Therapeutics Incorp is a precision oncology company developing medicines in areas of high unmet need for cancer patients. Its pipeline features selective KAT6A degraders and mutant selective JAK2V617F JH2 inhibitors, new approaches to clinically validated targets with transformative potential for patients. The company is also leveraging its expertise in targeted protein degradation to discover and develop next-generation degrader antibody conjugates (DACs) with novel payloads.
Related Stocks
Compare head-to-head: PRLD vs LLY·PRLD vs JNJ·PRLD vs ABBV·PRLD vs ABT
Price and fundamental data are delayed and provided for informational purposes only. Not investment advice. See our disclaimer.